← All Arbutus Biopharma CORP filings

Arbutus Biopharma CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ABUS
Arbutus Biopharma CORP
10-K: Arbutus Biopharma Secures Moderna Settlement, Advances HBV Pipeline
Arbutus Biopharma reports a significant patent settlement with Moderna for $950M noncontingent payment, while advancing its HBV pipeline and undergoing substantial corporate restructuring.
NASDAQ
ABUS
Arbutus Biopharma CORP
10-K: Arbutus Biopharma Reports 2024 Financial Results and Provides Business Update
Arbutus Biopharma focuses on advancing its hepatitis B programs and LNP delivery technology while streamlining operations and reducing workforce.
NASDAQ
ABUS
Arbutus Biopharma CORP
10-K: Arbutus Biopharma Outlines Capital Structure and Pipeline Progress in Annual 10-K Filing
Arbutus Biopharma's annual 10-K filing details its capital structure, ongoing clinical trials, and strategic focus on developing a functional cure for chronic hepatitis B.